** Shares of drug developer Mersana Therapeutics MRSN.O rise 5.38% to $1.38 premarket
** Co says U.S. FDA has granted additional fast track tag to its experimental drug XMT-1660
** The new tag is for the treatment of some patients with a type of breast cancer
** The FDA's Fast Track program is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need
** Separately, co announced data from an early-stage trial of the drug in patients with a type of breast cancer
** Stock fell 38.36% last year
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。